Every one of those 1 sits in a single category, regulation. Therapeutic Goods Administration (TGA) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 7, the average consequence score sits above the same-window beat average of 5.7.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Optellum
Every one of those 1 sits in a single category, regulation. Therapeutic Goods Administration (TGA) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 7, the average consequence score sits above the same-window beat average of 5.7. Source depth averages 3 original sources per story, versus 3.2 across the same-window beat baseline. We currently track 1 Healthcare story that mention Optellum, all published on February 27, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Optellum. Shared-story counts are live from our verified record — not editorial picks.
Optellum has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. This expansion allows Australian clinicians to utilize advanced imaging analytics to improve early lung cancer detection and streamline patient care pathways.